AUS
NZ
UK
CA
USA
IND
Highlights
- Smith & Nephew secured a 7.7% year-on-year increase in its underlying revenue in the third quarter of the fiscal year 2023.
- In the first half of the year 2023, the firm posted a revenue growth of 6.7% YoY, on a reported basis.
- In the month of November, the firm paid an interim dividend of 14.40 US cents per share, with an ex-dividend date of 05 October 2023.
FTSE 100 listed medical technology company Smith & Nephew PLC (LSE: SN.) has its operations spread across more than 100 countries supported by a team of over 17,500 professionals. In the third quarter of the fiscal year 2023, the company secured a 7.7% year-on-year increase in its underlying revenue. The revenue from the Orthopaedics division and Sports Medicine & ENT grew 8.3% and 11% YoY, respectively in the reporting period. The company undertook the first surgery employing its novel AETOS◊ Shoulder System and introduced its REGENETEN◊ Bioinductive Implant in Japan and India in Q3 FY23.
In the first half of the year 2023, the firm posted a revenue growth of 6.7% YoY, on a reported basis. On an underlying basis, the top-line business registered around 7.8% YoY growth for the six-month period. Smith & Nephew’s operating profit margin rose to ~10.0% in H1 FY23 from 9.3% in H1 FY22.
The company’s trading profit margin reduced to 15.3% in H1 FY23. However, the company is expecting its trading profit margin to be minimum 20% in FY25, propelled by higher productivity.
In the month of November, the firm paid an interim dividend of 14.40 US cents per share, with an ex-dividend date of 05 October 2023.
Top 10 Shareholders:
Around 22.73% of the total shareholdings in the firm are owned by its top ten shareholders. While BlackRock Institutional Trust Company, N.A. is the biggest shareholder with over 5.3% shareholding, the Vanguard Group, Inc. is the second biggest shareholder holding around 3.30% stake in Smith & Nephew.
Stock Price Performance
The stock price has gained approximately 4.56% in the last one month. It has declined by over 14% over the last six months. The stock’s 52-week low and high price stand at GBX 887.00 and GBX 1,316.75, respectively.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 06 December 2023. The reference data in this report has been partly sourced from EODHD/Others.
